San Diego’s Illumina is the world leader in gene sequencing technology — the ability to read and record DNA. Now, the billion-dollar company is buying another in a bid to expand its portfolio in ...

In ancient Greek lore, Proteus, son of Poseidon, held the allure of wisdom and foresight, yet could only be approached by those with the means to capture him. Much like this mythical figure, proteins, ...

Illumina first flagged the deal in June 2025 as part of a strategy to bolt protein readouts onto its sequencing ecosystem, according to Illumina. The seller, Standard BioTools, said it has now ...

Barcoding technologies that take advantage of the high information content that can be encoded in oligonucleotide sequences have enabled a wide array of applications in biotechnology, particularly ...

Protein sequencing presents different challenges than nucleic acid sequencing, meaning that proteomics has yet to benefit as much as genomics from the next-generation sequencing revolution. However, ...

Proteins, through their diversity, are vital determinants of phenotype and function. Humans possess potentially millions of protein variants (proteoforms), derived through mechanisms including ...

On Wednesday, Quantum-Si Incorporated (NASDAQ:QSI) stock traded over 100% higher after the protein sequencing company announced a collaboration with NVIDIA Corporation (NASDAQ:NVDA) to develop its new ...

Quantum-Si aims to revolutionize protein sequencing but faces significant technological and competitive challenges. Commercial reception to Quantum-Si's solutions has been lukewarm so far, suggesting ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based ...